Atea Pharmaceuticals (AVIR) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Kamada (KMDA) over the past year, gaining 68.7% versus a gain of 18.6%. Over five years, KMDA leads with a +49.7% price change compared with -87.2% for AVIR. Kamada is the larger company by market cap ($448.7 million vs $413.5 million), about 1.1 times the size.
Kamada pays a dividend yielding 3.22%, while Atea Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | KMDA |
|---|---|---|
| Share price | $5.16 | $7.78 |
| Market cap | $413.46M | $448.70M |
| 1-day change | +2.89% | -1.46% |
| YTD return | +40.34% | +11.76% |
| 1-year return | +68.69% | +18.65% |
| 5-year return | -87.25% | +49.72% |
| P/E ratio (TTM) | — | 20.46 |
| Forward P/E | — | 13.48 |
| EPS (TTM) | $-2.09 | $0.38 |
| Dividend yield | 0.00% | 3.22% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $6.45 | $9.35 |
| 52-week low | $2.87 | $6.55 |
| Distance from 52-week high | -20.08% | -16.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.74% | +73.63% |
| Average volume | 298.38K | 118.04K |
| Shares outstanding | 80.20M | 57.71M |
| Employees | 55 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed KMDA by 50.0 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
AVIR vs KMDA FAQ
Which is bigger, Atea Pharmaceuticals or Kamada?
Kamada (KMDA) is larger, with a market capitalization of $448.70M compared with $413.46M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or KMDA?
AVIR returned +68.69% over the past 12 months, compared with +18.65% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Atea Pharmaceuticals or Kamada?
Kamada pays a dividend yielding 3.22%, while Atea Pharmaceuticals does not currently pay a regular dividend.
Are Atea Pharmaceuticals and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.